Fractyl Health, Inc. Common Stock

Day range

$1.02 – $1.12

Open

$1.08

Prev close

$1.08

Volume

294.02K

Market cap

$14.33M

Shares out

13.26M

P/E

—

P/S

—

P/B

-8.60

P/FCF

—

ROE

6345.3%

ROA

-128.9%

Debt/Equity

-18.29

Div yield

0.00%

As of Oct 23, 2026

• Restructuring planOct 22, 2026

  On October 21, 2026, Fractyl Health, Inc. adopted a plan to sharpen its strategic focus on its Revita® program in connection with a strategic reprioritization. The Company estimates that it will incur charges of approximately $2 million for severance and other employee termination-related costs.

• Clinical trial resultsOct 16, 2026

  On October 16, 2026, the Company reported topline six-month results from its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled pivotal study evaluating the safety and efficacy of Revita in maintaining weight loss after GLP-1 based therapy discontinuation. The six-month co-primary endpoint was met, with Revita participants maintaining approximately 80% of their GLP-1-induced weight loss versus 67% for sham participants (p=0.0023).

• Stock splitOct 1, 2026

  On September 30, 2026, Fractyl Health, Inc. filed a Certificate of Amendment ... to effect a one-for-twelve (1-for-12) reverse stock split of its outstanding common stock. The Amendment will be effective at 5:00 p.m. Eastern Time on October 2, 2026.

• Special meeting resultsSep 24, 2026

  On September 24, 2026, Fractyl Health, Inc. held its Special Meeting of Stockholders. ... Proposal No. 1 ... to effect ... a reverse stock split of the Company's common stock at a ratio in the range of 1-for-5 to 1-for-15 ... was approved by the Company's stockholders.

• Investor presentationJul 15, 2026

  The Company will host a conference call and live audio webcast today, July 15, 2026 at 8:00 a.m., Eastern Time, to discuss the presentation of data described above. A copy of the presentation to be used by the Company during the conference call is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

Days to cover

1.2

Short interest

2.15M

Avg volume

1.79M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS
  negativeGlobeNewswire Inc.· Oct 20, 2026
• GUTS DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th
  negativeGlobeNewswire Inc.· Oct 19, 2026
• GUTS DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th
  negativeGlobeNewswire Inc.· Oct 17, 2026
• Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
  negativeGlobeNewswire Inc.· Oct 15, 2026
• Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th
  negativeGlobeNewswire Inc.· Oct 1, 2026